Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$21.28 USD
+0.22 (1.04%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $21.33 +0.05 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNDX 21.28 +0.22(1.04%)
Will SNDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
Other News for SNDX
Syndax price target lowered by $3 at Citi, here's why
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
First Week of June 21st Options Trading For Syndax Pharmaceuticals (SNDX)
Syndax management to meet with BTIG
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum